Post by Dave Copland

Thrilled to share news of our new publication in Molecular Therapy! Our study further elaborates the critical inflammatory pathways which are impacting ocular AAV gene therapy delivery. This work demonstrates a requisite role for pathogenic T cells in acute and subclinical responses, redefining mechanisms of AAV-induced inflammation. Beyond improving mechanistic understanding, it evidences support for T cell-targeted immunomodulation as a promising steroid-sparing strategy to enhance therapeutic outcomes and preserve long‑term ocular homeostasis in gene therapy. 👁️ Excited to see how this work can advance safer, more durable gene therapy for blinding diseases—and open the door to refined immunomodulatory strategies across the field. Amazing team effort from wonderful colleagues including Alison Clare, Andrew Dick, Kathryn Pepple and others across University of Bristol, University of Washington, UCL Institute of Ophthalmology, Cirrus Therapeutics, and only possible with generous support from Sight Research UK, The Underwood Trust, Medical Research Council, and NIHR Moorfields Biomedical Research Centre Huge congratulations to Philip Langer on this first author publication and exceptional work during his PhD! Read the full paper here: https://lnkd.in/edM6EdRu